Floatz logo

Entinostat

Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11

National Cancer Institute (NCI)Small moleculePhase 2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 2BB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 3BB
Azacitidine
National Cancer Institute (NCI)
Phase 2BB
CASPOFUNGIN
Children's Oncology Group
Phase 3BB
Fluconazole
Children's Oncology Group
Phase 3BB

View all 34 →

Same molecule, other indications

Entinostat is also rated in:

Stage IIIA Non-Small Cell Lung CancerDormant
BB
Indicative ·
69 / 100
View asset →
triple-negative breast carcinomaDormant
B
Indicative ·
63 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →